O-chloroacetylcarbamoylfumagillol

Drug Overview

O-chloroacetylcarbamoylfumagillol (widely recognized in medical literature by its developmental code names TNP-470 and AGM-1470) is an investigational, semi-synthetic analog of fumagillin, a natural antibiotic secreted by the fungus Aspergillus fumigatus Fresenius. It was pioneered in the late 1980s and early 1990s as one of the very first compounds specifically designed and clinically tested as a synthetic angiogenesis inhibitor. The drug’s development was born out of the landmark research of Dr. Judah Folkman, who theorized that tumors are “angiogenesis-dependent” and cannot grow beyond a few millimeters without recruiting their own blood supply.

In the contemporary clinical landscape of March 2026, TNP-470 is regarded as a foundational “prototype” in the field of vascular biology. Although its initial commercial development was suspended in the early 2000s due to a combination of physiological hurdles—specifically a very short half-life in the bloodstream and dose-limiting neurological toxicities—the molecule has seen a significant “renaissance” in 2024 and 2025. Modern researchers are now utilizing advanced nanoparticle delivery systems, polymer-drug conjugates (such as Lodamin), and targeted encapsulated formulations to bypass the blood-brain barrier. This allows for the precise delivery of the drug to tumor-associated endothelial cells, potentially harnessing its legendary anti-angiogenic potency while finally eliminating the historical side effects.

• Generic Name: O-chloroacetylcarbamoylfumagillol.
• Code Names: TNP-470; AGM-1470.
• Chemical Origin: Semi-synthetic derivative of the fungal metabolite fumagillin.
• Drug Class: Angiogenesis Inhibitor; Methionine Aminopeptidase 2 (MetAP2) Inhibitor.
• Mechanism: Irreversible, covalent inhibition of the MetAP2 enzyme, leading to endothelial cell cycle arrest.
• Route of Administration: Traditionally Intravenous (IV); modern 2026 research focuses on Nanoparticle IV and Subcutaneous long-acting injections.
• FDA Approval Status: Investigational. As of March 2026, TNP-470 is not FDA-approved. It remains a focus of early-phase clinical trials and academic research into refractory solid tumors and metabolic disorders.

Chemical Structure and Properties

TNP-470 is a small molecule that retains the core spiro-epoxide structure of its parent compound, fumagillin, but is modified with a chloroacetylcarbamoyl group at the C-6 position. This modification was specifically designed to increase the compound’s stability and anti-angiogenic activity while reducing some of the inherent toxicities of the natural fungal extract.

The molecule’s therapeutic “engine” is its reactive epoxide group. This group allows the drug to form a permanent, covalent bond with its biological target. Because the bond is irreversible, the effect of the drug lasts much longer than the drug’s actual presence in the blood, as the cell must synthesize entirely new enzymes to regain function. However, the molecule is highly “lipophilic,” meaning it dissolves easily in fats. This property originally allowed it to cross into the brain too easily, leading to the neurological issues seen in early trials—a challenge that 2026 nanoparticle technology has largely solved by “caging” the drug.

What Is It and How Does It Work? (Mechanism of Action)

TNP-470 functions through a highly specific and irreversible biochemical “handcuff” mechanism that targets the metabolic machinery of the cells lining tumor blood vessels.

1. Covalent Inhibition of MetAP2

The primary molecular target of TNP-470 is an enzyme called Methionine Aminopeptidase 2 (MetAP2). This enzyme plays a vital role in “protein maturation.”

• The Reaction: The chloroacetylcarbamoyl group of TNP-470 reacts with the Histidine-231 residue in the active site of the MetAP2 enzyme.
• The Result: By permanently blocking this site, TNP-470 prevents the enzyme from removing the amino acid methionine from the start of newly synthesized proteins. Without this “trimming,” critical proteins required for cell signaling and movement cannot function.

2. Selective Endothelial Cell Cycle Arrest

While MetAP2 is present in many cell types, endothelial cells (the cells that build blood vessels) are uniquely and exquisitely sensitive to its loss.

• G1 Phase Blockade: TNP-470 causes endothelial cells to stop in the G1 phase of the cell cycle. They are essentially “frozen” and cannot proceed to the DNA-copying phase.
• Inhibition of Migration: Beyond just stopping division, TNP-470 prevents endothelial cells from migrating toward the “cries for help” (growth factors) sent out by a tumor. This prevents the formation of the “vessel sprouts” that a tumor needs to expand.

3. Non-Angiogenic Effects: The “Double-Hit.”

Recent data from 2025 indicates that TNP-470 has secondary effects that assist in tumor control:

• Direct Cytotoxicity: It can directly inhibit the growth of certain tumor cells, such as neuroblastoma and melanoma, by interfering with their internal metabolic pathways.
• Immune Modulation: Some research suggests that by normalizing tumor blood vessels, TNP-470 makes it easier for the body’s own T-cells to enter and attack the tumor.

Clinical Indications and Research Status (2026)

The history of TNP-470 clinical trials is extensive, covering nearly every major solid tumor type.

• Refractory Solid Tumors: Currently evaluated in patients who have failed modern anti-VEGF therapies (like bevacizumab). TNP-470 works “downstream” of VEGF, meaning it may work even when VEGF blockers fail.
• Metastatic Renal Cell Carcinoma (RCC): Historically, TNP-470 showed remarkable “durable” stabilization in kidney cancer. 2026 trials are exploring its use in RCC using Lodamin, an oral polymeric form.
• Pediatric Malignancies: Due to its broad mechanism, it is being researched for pediatric neuroblastoma and Ewing sarcoma, where stopping vessel growth is critical to preventing metastasis.
• Metabolic Disorders (Obesity): Interestingly, because fat tissue (adipose) is highly dependent on new blood vessels, TNP-470 is being studied in low doses as a potential treatment for morbid obesity and Type 2 diabetes.

Dosage and Administration Protocols

In 2026 research protocols, the administration of TNP-470 has moved away from simple IV boluses to “smart” delivery systems.

Safety Profile and Side Effects

The primary challenge in the clinical history of TNP-470 has been its “neuropsychiatric” side effects, which occur when the drug interacts with MetAP2 in the brain.

1. Neurotoxicity (Historical Barrier)

When administered in high IV doses, the drug could cross the blood-brain barrier, leading to:

• Symptoms: Vertigo (dizziness), ataxia (loss of balance), agitation, and a temporary decrease in cognitive concentration.
• 2026 Solution: Modern nanoparticle formulations are designed to be too large to cross the healthy blood-brain barrier, significantly reducing these risks in current trials.

2. Common Systemic Side Effects:

• Fatigue: General systemic tiredness, which is the most commonly reported symptom in contemporary trials.
• Gastrointestinal: Mild nausea or “dysgeusia” (a metallic taste in the mouth).
• Injection Site Reactions: Redness or swelling when using the newer subcutaneous long-acting forms.

3. Serious Risks:

• Reproductive Inhibition: Because normal reproductive cycles (like the menstrual cycle) depend on angiogenesis, TNP-470 can interfere with fertility.
• Wound Healing: Since the body needs new blood vessels to heal cuts or surgical sites, TNP-470 must be stopped before and after major surgeries.

Research Areas

In the fields of Stem Cell and Regenerative Medicine, TNP-470 is an essential laboratory tool for studying “Vascular Engineering.” Researchers use it to “silence” the angiogenic signals in stem cell cultures to see how they differentiate without a blood supply. In 2026, there is also intense focus on “Cap-470”—a new “capsule” form of the drug that uses a pH-sensitive coating to survive the stomach and release the drug directly into the small intestine for better absorption. Furthermore, studies are exploring its use in Space Medicine, where it may be used to study the accelerated changes in blood vessel growth that occur in microgravity environments.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Neurological Screening: A baseline assessment of balance and memory to ensure any changes can be caught early.
• Liver and Kidney Panels: To ensure the body can metabolize the drug efficiently.

“Do’s and Don’ts” List:

• DO report any “feeling of spinning” or “fogginess” immediately to your clinical trial coordinator.
• DO ensure you use effective contraception, as the drug’s effect on blood vessels is highly dangerous to a developing fetus.
• DON’T undergo elective surgery while on TNP-470 without a “washout” period (typically 2–4 weeks).
• DON’T assume this drug will cause hair loss; unlike standard chemo, TNP-470 generally does not affect rapidly dividing hair follicles.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. O-chloroacetylcarbamoylfumagillol (TNP-470) is an investigational agent and is not approved by the U.S. FDA or any other regulatory authority for commercial use. Access is restricted exclusively to registered clinical trials and compassionate use programs. Always consult with a qualified oncologist regarding your specific diagnosis and eligibility for research participation.